94.15
price up icon0.51%   0.48
after-market アフターアワーズ: 94.15
loading
前日終値:
$93.67
開ける:
$93.62
24時間の取引高:
13.74M
Relative Volume:
9.90
時価総額:
$7.12B
収益:
$35.93M
当期純損益:
$-244.56M
株価収益率:
-23.84
EPS:
-3.95
ネットキャッシュフロー:
$-157.31M
1週間 パフォーマンス:
+38.01%
1か月 パフォーマンス:
+43.00%
6か月 パフォーマンス:
+123.69%
1年 パフォーマンス:
+88.45%
1日の値動き範囲:
Value
$93.52
$94.30
1週間の範囲:
Value
$66.13
$94.56
52週間の値動き範囲:
Value
$33.19
$94.56

Merus N V Stock (MRUS) Company Profile

Name
名前
Merus N V
Name
セクター
Healthcare (1147)
Name
電話
31 030 253 8800
Name
住所
YALELAAN 62, 3584 CM UTRECHT
Name
職員
260
Name
Twitter
@MerusNV
Name
次回の収益日
2024-10-31
Name
最新のSEC提出書
Name
MRUS's Discussions on Twitter

MRUS を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
MRUS
Merus N V
94.15 7.10B 35.93M -244.56M -157.31M -3.95
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
391.64 101.35B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
456.00 58.66B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
562.27 59.43B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ARGX
Argen X Se Adr
737.56 44.01B 3.06B 1.28B 447.35M 21.30
Biotechnology icon
ONC
Beone Medicines Ltd Adr
340.70 36.56B 3.81B -644.79M -669.77M -6.24

Merus N V Stock (MRUS) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-09-17 開始されました Barclays Overweight
2025-08-25 開始されました Alliance Global Partners Buy
2025-02-13 開始されました Piper Sandler Overweight
2025-02-07 開始されました Wells Fargo Overweight
2024-11-21 開始されました Goldman Buy
2024-10-24 開始されました UBS Buy
2024-03-28 開始されました Truist Buy
2024-03-04 繰り返されました Needham Buy
2023-11-02 開始されました Canaccord Genuity Buy
2023-08-21 開始されました TD Cowen Outperform
2022-08-02 開始されました Stifel Buy
2022-02-11 開始されました BMO Capital Markets Outperform
2022-02-10 開始されました Needham Buy
2021-11-17 再開されました Guggenheim Buy
2021-06-07 アップグレード Citigroup Neutral → Buy
2021-04-08 開始されました William Blair Outperform
2021-03-16 開始されました SVB Leerink Outperform
2020-06-26 開始されました H.C. Wainwright Buy
2020-05-27 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2019-11-20 再開されました Guggenheim Buy
2019-06-28 開始されました ROTH Capital Buy
2019-04-12 再開されました Guggenheim Buy
2019-04-03 アップグレード RBC Capital Mkts Sector Perform → Outperform
2019-03-27 開始されました Berenberg Buy
2018-01-02 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2017-09-15 開始されました RBC Capital Mkts Outperform
2017-03-21 ダウングレード Citigroup Buy → Neutral
2016-12-22 アップグレード Citigroup Neutral → Buy
2016-11-07 ダウングレード Citigroup Buy → Neutral
2016-06-13 開始されました Citigroup Buy
2016-06-13 開始されました Guggenheim Buy
2016-06-13 開始されました Wedbush Outperform
すべてを表示

Merus N V (MRUS) 最新ニュース

pulisher
Sep 30, 2025

MERUS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Merus N.V.MRUS - The AI Journal

Sep 30, 2025
pulisher
Sep 30, 2025

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of 1st Merus N.V. (NASDAQ: MRUS) - PR Newswire

Sep 30, 2025
pulisher
Sep 30, 2025

Latham & Watkins Advises Merus in US$8 Billion Acquisition by Genmab - Latham & Watkins LLP

Sep 30, 2025
pulisher
Sep 30, 2025

Genmab Nears Deal to Buy Cancer Drugmaker Merus - MSN

Sep 30, 2025
pulisher
Sep 30, 2025

This Maplebear Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday - Benzinga

Sep 30, 2025
pulisher
Sep 30, 2025

MRUS Analyst Rating Update: Guggenheim Downgrades to Neutral | M - GuruFocus

Sep 30, 2025
pulisher
Sep 30, 2025

MRUS Analyst Rating Update: Canaccord Genuity Adjusts PT and Rat - GuruFocus

Sep 30, 2025
pulisher
Sep 30, 2025

Merus (MRUS) Sees Rating Downgrade and Target Price Raise by Wells Fargo | MRUS Stock News - GuruFocus

Sep 30, 2025
pulisher
Sep 30, 2025

Merus (MRUS) Receives Rating Downgrade by LifeSci Capital | MRUS Stock News - GuruFocus

Sep 30, 2025
pulisher
Sep 30, 2025

Barclays Downgrades MRUS, Lowers Price Target Amid Market Adjustments | MRUS Stock News - GuruFocus

Sep 30, 2025
pulisher
Sep 30, 2025

Merus (MRUS) Sees Downgrade from UBS with Raised Price Target | MRUS Stock News - GuruFocus

Sep 30, 2025
pulisher
Sep 30, 2025

Merus (NASDAQ:MRUS) Receives "Market Perform" Rating from Lifesci Capital - MarketBeat

Sep 30, 2025
pulisher
Sep 30, 2025

Barclays Downgrades Merus to Equalweight From Overweight, Adjusts Price Target to $97 From $112 - MarketScreener

Sep 30, 2025
pulisher
Sep 30, 2025

BMO Capital Downgrades Merus to Market Perform From Outperform, Adjusts Price Target to $97 From $110 - MarketScreener

Sep 30, 2025
pulisher
Sep 30, 2025

Merus Stock Soars To All-Time High As Genmab Announces $8B Takeover — Analysts Turn Cautious, Retail Crowd Cheers The Deal - Stocktwits

Sep 30, 2025
pulisher
Sep 30, 2025

Merus (NASDAQ:MRUS) Rating Lowered to "Hold" at Wells Fargo & Company - MarketBeat

Sep 30, 2025
pulisher
Sep 30, 2025

Genmab Bets Big On Cancer With $8 Billion Merus Deal - Finimize

Sep 30, 2025
pulisher
Sep 30, 2025

Merus Reaches Analyst Target Price - Nasdaq

Sep 30, 2025
pulisher
Sep 30, 2025

MRUS Stock Downgraded: HC Wainwright & Co. Lowers Price Target | - GuruFocus

Sep 30, 2025
pulisher
Sep 30, 2025

Genmab to acquire Merus shares for $8bn - Yahoo Finance

Sep 30, 2025
pulisher
Sep 30, 2025

Barclays downgrades Merus stock to Equalweight, cuts price target on valuation - Investing.com

Sep 30, 2025
pulisher
Sep 30, 2025

Guggenheim downgrades Merus stock to Neutral following Genmab acquisition - Investing.com

Sep 30, 2025
pulisher
Sep 30, 2025

Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model - AD HOC NEWS

Sep 30, 2025
pulisher
Sep 30, 2025

EQT Life Sciences portfolio company Merus to be acquired by Genmab in an all-cash USD 8.0 billion transaction - Yahoo Finance

Sep 30, 2025
pulisher
Sep 30, 2025

EQT Is Shareholder in Merus, Acquired by Denmark's Genmab - MarketScreener

Sep 30, 2025
pulisher
Sep 30, 2025

Merus stock rating downgraded by UBS after Genmab acquisition - Investing.com India

Sep 30, 2025
pulisher
Sep 30, 2025

Genmab to acquire Merus for $8 billion in cash deal By Investing.com - Investing.com Australia

Sep 30, 2025
pulisher
Sep 30, 2025

What’s the recovery path for long term holders of Merus N.V.Market Volume Report & Smart Money Movement Alerts - newser.com

Sep 30, 2025
pulisher
Sep 30, 2025

Genmab to acquire Merus for $8 billion in cash deal - Investing.com

Sep 30, 2025
pulisher
Sep 29, 2025

Genmab swallows Merus in US$8bn deal - European Biotechnology Magazine

Sep 29, 2025
pulisher
Sep 29, 2025

Genmab adding late-stage bispecific in $8B Merus acquisition - BioWorld MedTech

Sep 29, 2025
pulisher
Sep 29, 2025

Mid Cap Stocks To ConsiderSeptember 29th - MarketBeat

Sep 29, 2025
pulisher
Sep 29, 2025

Will Merus N.V. stock see PE expansionLong Setup & Risk Adjusted Swing Trade Ideas - newser.com

Sep 29, 2025
pulisher
Sep 29, 2025

Merus N.V. Stock: Analyzing Recent Fluctuations - timothysykes.com

Sep 29, 2025
pulisher
Sep 29, 2025

Merus N.V. Soars on $8 Billion Genmab Acquisition, Propelled by Oncology Pipeline Successes - FinancialContent

Sep 29, 2025
pulisher
Sep 29, 2025

Leadership Changes and Bold Moves Shake Global Drugmakers - Devdiscourse

Sep 29, 2025
pulisher
Sep 29, 2025

Merus (MRUS) Experiences Surge with Significant Stock Price Incr - GuruFocus

Sep 29, 2025
pulisher
Sep 29, 2025

Genmab’s $8B Merus takeout is latest push toward full ownership of programs - biocentury.com

Sep 29, 2025
pulisher
Sep 29, 2025

Can Merus Sustain The Leap? - StocksToTrade

Sep 29, 2025
pulisher
Sep 29, 2025

Transcript : Genmab A/S, Merus N.V.M&A Call - MarketScreener

Sep 29, 2025
pulisher
Sep 29, 2025

MRUS: Truist Securities Downgrades Rating, Raises Price Target | MRUS Stock News - GuruFocus

Sep 29, 2025
pulisher
Sep 29, 2025

Promising Medical Stocks To Keep An Eye OnSeptember 29th - MarketBeat

Sep 29, 2025
pulisher
Sep 29, 2025

Genmab to Acquire Merus in $8 Billion Biotech Deal - USA Herald

Sep 29, 2025
pulisher
Sep 29, 2025

MRUS Shares Surge Amid Acquisition Talks - timothysykes.com

Sep 29, 2025
pulisher
Sep 29, 2025

4 Firms Advise On Genmab's $8B Merus Acquisition Plan - Law360

Sep 29, 2025
pulisher
Sep 29, 2025

HC Wainwright Downgrades Merus to Neutral From Buy, Price Target at $97 - MarketScreener

Sep 29, 2025
pulisher
Sep 29, 2025

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates EA, MRUS, BRY, SMLR on Behalf of Shareholders - Benzinga

Sep 29, 2025
pulisher
Sep 29, 2025

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire

Sep 29, 2025
pulisher
Sep 29, 2025

A&O Shearman advises Genmab on its proposed USD8 billion acquisition of Merus - A&O Shearman

Sep 29, 2025
pulisher
Sep 29, 2025

Genmab to buy Dutch cancer drugmaker Merus for $8 billion - Reuters

Sep 29, 2025
pulisher
Sep 29, 2025

Genmab Makes $8 Billion Bet On Cancer Drugmaker Merus - Finimize

Sep 29, 2025

Merus N V (MRUS) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$20.66
price down icon 2.36%
$84.81
price up icon 1.10%
$30.67
price up icon 4.57%
$98.62
price up icon 0.53%
$144.01
price up icon 1.67%
biotechnology ONC
$340.70
price up icon 2.36%
大文字化:     |  ボリューム (24 時間):